Literature DB >> 10738303

MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma.

L V Debelenko1, J I Swalwell, M J Kelley, E Brambilla, P Manickam, G Baibakov, S K Agarwal, A M Spiegel, S J Marx, S C Chandrasekharappa, F S Collins, W D Travis, M R Emmert-Buck.   

Abstract

Neuroendocrine tumors of the lung consist of a spectrum of neoplasms, including typical carcinoids, atypical carcinoids, large-cell neuroendocrine carcinomas (LCNEC), and small-cell lung carcinomas (SCLC). We previously reported frequent inactivation of the gene responsible for multiple endocrine neoplasia type 1 (MEN1) in both typical and atypical carcinoid tumors. In the present study, we extend the analysis of human NE lung tumors to include 9 primary SCLCs, 36 SCLC cell lines, and 13 primary LCNECs for MEN1 gene inactivation. In SCLC, loss of heterozygosity (LOH) at the MEN1 gene on chromosome band 11q13 was detected in one primary tumor and two cell lines. The coding sequence and splice junctions of the MEN1 gene were screened for mutations in all 44 tumors and cell lines, and no mutations were detected. Northern blot analysis of 13 SCLC cell lines showed the MEN1 transcript to be present and of normal size. In LCNECs, a somatic frameshift in the MEN1 gene (1226delC) was found in one of 13 tumors, representing the first mutation observed outside the spectrum of neoplasms associated with MEN1. Interestingly, neither a deletion nor a mutation was detected in the other allele, and wild-type mRNA sequence was expressed in the tumor, suggesting that the MEN1 gene was not inactivated by a conventional two-hit mechanism. The data support the hypothesis that SCLC and lung carcinoids develop via distinct molecular pathways; however, further investigation is necessary to determine the significance of the MEN1 gene mutation observed in a single case of LCNEC. Published 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738303     DOI: 10.1002/(sici)1098-2264(200005)28:1<58::aid-gcc7>3.0.co;2-2

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR.

Authors:  L Tauchmanovà; M Pensabene; I Capuano; I Spagnoletti; P Zeppa; S Del Vecchio; M Mainenti; G De Rosa; A Colao; A Contegiacomo
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

Review 2.  Therapeutic biomarkers in lung neuroendocrine neoplasia.

Authors:  Luisella Righi; Marco Volante; Ida Rapa; Simona Vatrano; Giuseppe Pelosi; Mauro Papotti
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

3.  Rare airway tumors: an update on current diagnostic and management strategies.

Authors:  Marwan Saoud; Monali Patil; Samjot Singh Dhillon; Saraswati Pokharel; Anthony Picone; Mark Hennon; Sai Yendamuri; Kassem Harris
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

4.  Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.

Authors:  P Lecomte; C Binquet; M Le Bras; A Tabarin; C Cardot-Bauters; F Borson-Chazot; C Lombard-Bohas; E Baudin; B Delemer; M Klein; B Vergès; T Aparicio; E Cosson; A Beckers; Ph Caron; O Chabre; Ph Chanson; H Du Boullay; I Guilhem; P Niccoli; V Rohmer; J Guigay; C Vulpoi; J Y Scoazec; P Goudet
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

5.  Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift.

Authors:  Alessandra Fabbri; Mara Cossa; Angelica Sonzogni; Paolo Bidoli; Stefania Canova; Diego Cortinovis; Maria Ida Abbate; Fiorella Calabrese; Nazarena Nannini; Francesca Lunardi; Giulio Rossi; Stefano La Rosa; Carlo Capella; Elena Tamborini; Federica Perrone; Adele Busico; Iolanda Capone; Barbara Valeri; Ugo Pastorino; Adriana Albini; Giuseppe Pelosi
Journal:  Virchows Arch       Date:  2017-04-27       Impact factor: 4.064

Review 6.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

7.  CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas.

Authors:  Giuseppe Pelosi; Michele Masullo; Maria Elena Leon; Giulia Veronesi; Lorenzo Spaggiari; Felice Pasini; Angelica Sonzogni; Antonio Iannucci; Enrica Bresaola; Giuseppe Viale
Journal:  Virchows Arch       Date:  2004-09-16       Impact factor: 4.064

8.  Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.

Authors:  Giuseppe Pelosi; Fabrizio Bianchi; Elisa Dama; Michele Simbolo; Andrea Mafficini; Angelica Sonzogni; Sara Pilotto; Sergio Harari; Mauro Papotti; Marco Volante; Gabriella Fontanini; Luca Mastracci; Adriana Albini; Emilio Bria; Fiorella Calabrese; Aldo Scarpa
Journal:  Virchows Arch       Date:  2018-02-01       Impact factor: 4.064

9.  Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP β/ζ signaling by menin.

Authors:  Z-J Feng; S-B Gao; Y Wu; X-F Xu; X Hua; G-H Jin
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.